5PSQ-035 Relevance of fluoroquinolone prescription in hospital

BackgroundFluoroquinolones are frequently used in hospital for many indications. However, overuse or incorrect utilisation may cause resistance to these antibiotics. Furthermore, we had to analyse the consequences of a recently ofloxacine suppression from our hospital antibiotic list.PurposeWe wante...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A180-A181
Hauptverfasser: Taouk, B, Taouk, JB, Pavel, S, Lesauvage, F, Gabriel, L, Danieau, F, Guarino, V, Schemoul-Berton, E, Oger, F, Fournel, C, Lauby, V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A181
container_issue Suppl 1
container_start_page A180
container_title European journal of hospital pharmacy. Science and practice
container_volume 25
creator Taouk, B
Taouk, JB
Pavel, S
Lesauvage, F
Gabriel, L
Danieau, F
Guarino, V
Schemoul-Berton, E
Oger, F
Fournel, C
Lauby, V
description BackgroundFluoroquinolones are frequently used in hospital for many indications. However, overuse or incorrect utilisation may cause resistance to these antibiotics. Furthermore, we had to analyse the consequences of a recently ofloxacine suppression from our hospital antibiotic list.PurposeWe wanted to know the level of relevance of fluoroquinolone prescription including: indication, fluoroquinolone molecule choice, dosage (including CKD-EPI based dose reduction), duration, route, eventual association, compliance with the antibiogram, drug interaction and catch of fluoroquinolone from 6 months before.Material and methodsWe carried out a 3 month transversal retrospective study. Between February and April 2017 each nominal prescription of fluoroquinolone was included using our pharmacy validation software. All services were included except intensives care units and emergencies. Then an intern in the pharmacy processed analyses of the relevance of the previous parameters with the help of senior infectious disease staff. The reference guideline used for relevance and analysis was the 2015 French Spoken Infectious Diseases Society (SPILF) recommendations.ResultsTwo hundred and six patients were included. The most recovered fluoroquinolone was levofloxacine 47.1% (95% CI: 40.3 to 53. 9). The average duration of treatment was 12 days (95% CI: 10.3 to 13.6). The most used route was oral 81.7% (95% CI: 76.2 to 87.2). In a large majority of fluoroquinolone prescription was probabilistic 60% (95% CI: 53.4 to 67.7).Analysis of relevance showed that indication was respected in 84.7% (95% CI: 79.5 to 89.8) of cases. The association of correct duration, dosage, molecule used and route was observed in 63.7% (95% CI: 53.8 to 73.6). 70.8% (95% CI: 58 to 83.7) of renal insufficiency patients (CKD-EPI
doi_str_mv 10.1136/ejhpharm-2018-eahpconf.389
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2010330170</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2099-2e269d1e167bf964942852264fd1360afa99c5443043a30b56e0155c5c695c6e3</originalsourceid><addsrcrecordid>eNp9UctqwzAQFKWFhjT_YNqzU71Wti6lJfQFgb7PQnbkWsGWXNkJ9NZLf7RfUps8oJcell3Y2WFmB6FTgqeEMHFulmVT6lDHFJM0Nrpscu-KKUvlARpRzJNYSsEP9zOIYzRpW5thYD2IMzlCl_D48hRjBj9f38-mMmvtchP5IiqqlQ_-Y2Wdr7wzURNMmwfbdNa7yLqo9G1jO12doKNCV62ZbPsYvd1cv87u4vnD7f3sah5nFEsZU0OFXBBDRJIVvSrJaQqUCl4seitYF1rKHDhnmDPNcAbCYAKQQy5kX4aN0cWGt1lltVnkxnVBV6oJttbhU3lt1d-Ns6V692uVAAMicU9wtiUYbJm2U0u_Cq7XrCgATYQgHP5FYYIZwyQZuGCDyurlXgLBaohF7WIZDlK1i0X1H2e_0CSFkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2010330170</pqid></control><display><type>article</type><title>5PSQ-035 Relevance of fluoroquinolone prescription in hospital</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Taouk, B ; Taouk, JB ; Pavel, S ; Lesauvage, F ; Gabriel, L ; Danieau, F ; Guarino, V ; Schemoul-Berton, E ; Oger, F ; Fournel, C ; Lauby, V</creator><creatorcontrib>Taouk, B ; Taouk, JB ; Pavel, S ; Lesauvage, F ; Gabriel, L ; Danieau, F ; Guarino, V ; Schemoul-Berton, E ; Oger, F ; Fournel, C ; Lauby, V</creatorcontrib><description>BackgroundFluoroquinolones are frequently used in hospital for many indications. However, overuse or incorrect utilisation may cause resistance to these antibiotics. Furthermore, we had to analyse the consequences of a recently ofloxacine suppression from our hospital antibiotic list.PurposeWe wanted to know the level of relevance of fluoroquinolone prescription including: indication, fluoroquinolone molecule choice, dosage (including CKD-EPI based dose reduction), duration, route, eventual association, compliance with the antibiogram, drug interaction and catch of fluoroquinolone from 6 months before.Material and methodsWe carried out a 3 month transversal retrospective study. Between February and April 2017 each nominal prescription of fluoroquinolone was included using our pharmacy validation software. All services were included except intensives care units and emergencies. Then an intern in the pharmacy processed analyses of the relevance of the previous parameters with the help of senior infectious disease staff. The reference guideline used for relevance and analysis was the 2015 French Spoken Infectious Diseases Society (SPILF) recommendations.ResultsTwo hundred and six patients were included. The most recovered fluoroquinolone was levofloxacine 47.1% (95% CI: 40.3 to 53. 9). The average duration of treatment was 12 days (95% CI: 10.3 to 13.6). The most used route was oral 81.7% (95% CI: 76.2 to 87.2). In a large majority of fluoroquinolone prescription was probabilistic 60% (95% CI: 53.4 to 67.7).Analysis of relevance showed that indication was respected in 84.7% (95% CI: 79.5 to 89.8) of cases. The association of correct duration, dosage, molecule used and route was observed in 63.7% (95% CI: 53.8 to 73.6). 70.8% (95% CI: 58 to 83.7) of renal insufficiency patients (CKD-EPI &lt;60 ml/mn) received the exact dose reduction based on CKD-EPI. We identified the presence of a drug interaction in 13.8% (95% CI: 9 to 18,8) of prescriptions. Antibiotic association was noted in 42,7% (95% CI: 35,7 to 49,7) of prescriptions; only a few, 43.6%, (95% CI: 32.59 to 54.59) were relevant.ConclusionEven in the context of important changes in the fluoroquinolone list in our hospital, prescriptions are mostly relevant for indications and molecule choice. Serious medical information seems to be necessary concerning antibiotics associations. Adequate fluoroquinolone reduction dose must be a priority for renal insufficiency patients. Solutions available may be a special control using the biological software allied with pharmaceutical analysis targeted at low CKD-EPI patients.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2018-eahpconf.389</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Antibiotics ; Associations ; Drug dosages ; Drug interactions ; Hospitals ; Infectious diseases ; Pharmacy ; Prescriptions ; Section 5: Patient safety and quality assurance</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A180-A181</ispartof><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2018 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535190/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535190/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Taouk, B</creatorcontrib><creatorcontrib>Taouk, JB</creatorcontrib><creatorcontrib>Pavel, S</creatorcontrib><creatorcontrib>Lesauvage, F</creatorcontrib><creatorcontrib>Gabriel, L</creatorcontrib><creatorcontrib>Danieau, F</creatorcontrib><creatorcontrib>Guarino, V</creatorcontrib><creatorcontrib>Schemoul-Berton, E</creatorcontrib><creatorcontrib>Oger, F</creatorcontrib><creatorcontrib>Fournel, C</creatorcontrib><creatorcontrib>Lauby, V</creatorcontrib><title>5PSQ-035 Relevance of fluoroquinolone prescription in hospital</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundFluoroquinolones are frequently used in hospital for many indications. However, overuse or incorrect utilisation may cause resistance to these antibiotics. Furthermore, we had to analyse the consequences of a recently ofloxacine suppression from our hospital antibiotic list.PurposeWe wanted to know the level of relevance of fluoroquinolone prescription including: indication, fluoroquinolone molecule choice, dosage (including CKD-EPI based dose reduction), duration, route, eventual association, compliance with the antibiogram, drug interaction and catch of fluoroquinolone from 6 months before.Material and methodsWe carried out a 3 month transversal retrospective study. Between February and April 2017 each nominal prescription of fluoroquinolone was included using our pharmacy validation software. All services were included except intensives care units and emergencies. Then an intern in the pharmacy processed analyses of the relevance of the previous parameters with the help of senior infectious disease staff. The reference guideline used for relevance and analysis was the 2015 French Spoken Infectious Diseases Society (SPILF) recommendations.ResultsTwo hundred and six patients were included. The most recovered fluoroquinolone was levofloxacine 47.1% (95% CI: 40.3 to 53. 9). The average duration of treatment was 12 days (95% CI: 10.3 to 13.6). The most used route was oral 81.7% (95% CI: 76.2 to 87.2). In a large majority of fluoroquinolone prescription was probabilistic 60% (95% CI: 53.4 to 67.7).Analysis of relevance showed that indication was respected in 84.7% (95% CI: 79.5 to 89.8) of cases. The association of correct duration, dosage, molecule used and route was observed in 63.7% (95% CI: 53.8 to 73.6). 70.8% (95% CI: 58 to 83.7) of renal insufficiency patients (CKD-EPI &lt;60 ml/mn) received the exact dose reduction based on CKD-EPI. We identified the presence of a drug interaction in 13.8% (95% CI: 9 to 18,8) of prescriptions. Antibiotic association was noted in 42,7% (95% CI: 35,7 to 49,7) of prescriptions; only a few, 43.6%, (95% CI: 32.59 to 54.59) were relevant.ConclusionEven in the context of important changes in the fluoroquinolone list in our hospital, prescriptions are mostly relevant for indications and molecule choice. Serious medical information seems to be necessary concerning antibiotics associations. Adequate fluoroquinolone reduction dose must be a priority for renal insufficiency patients. Solutions available may be a special control using the biological software allied with pharmaceutical analysis targeted at low CKD-EPI patients.No conflict of interest</description><subject>Antibiotics</subject><subject>Associations</subject><subject>Drug dosages</subject><subject>Drug interactions</subject><subject>Hospitals</subject><subject>Infectious diseases</subject><subject>Pharmacy</subject><subject>Prescriptions</subject><subject>Section 5: Patient safety and quality assurance</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9UctqwzAQFKWFhjT_YNqzU71Wti6lJfQFgb7PQnbkWsGWXNkJ9NZLf7RfUps8oJcell3Y2WFmB6FTgqeEMHFulmVT6lDHFJM0Nrpscu-KKUvlARpRzJNYSsEP9zOIYzRpW5thYD2IMzlCl_D48hRjBj9f38-mMmvtchP5IiqqlQ_-Y2Wdr7wzURNMmwfbdNa7yLqo9G1jO12doKNCV62ZbPsYvd1cv87u4vnD7f3sah5nFEsZU0OFXBBDRJIVvSrJaQqUCl4seitYF1rKHDhnmDPNcAbCYAKQQy5kX4aN0cWGt1lltVnkxnVBV6oJttbhU3lt1d-Ns6V692uVAAMicU9wtiUYbJm2U0u_Cq7XrCgATYQgHP5FYYIZwyQZuGCDyurlXgLBaohF7WIZDlK1i0X1H2e_0CSFkw</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Taouk, B</creator><creator>Taouk, JB</creator><creator>Pavel, S</creator><creator>Lesauvage, F</creator><creator>Gabriel, L</creator><creator>Danieau, F</creator><creator>Guarino, V</creator><creator>Schemoul-Berton, E</creator><creator>Oger, F</creator><creator>Fournel, C</creator><creator>Lauby, V</creator><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20180301</creationdate><title>5PSQ-035 Relevance of fluoroquinolone prescription in hospital</title><author>Taouk, B ; Taouk, JB ; Pavel, S ; Lesauvage, F ; Gabriel, L ; Danieau, F ; Guarino, V ; Schemoul-Berton, E ; Oger, F ; Fournel, C ; Lauby, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2099-2e269d1e167bf964942852264fd1360afa99c5443043a30b56e0155c5c695c6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibiotics</topic><topic>Associations</topic><topic>Drug dosages</topic><topic>Drug interactions</topic><topic>Hospitals</topic><topic>Infectious diseases</topic><topic>Pharmacy</topic><topic>Prescriptions</topic><topic>Section 5: Patient safety and quality assurance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taouk, B</creatorcontrib><creatorcontrib>Taouk, JB</creatorcontrib><creatorcontrib>Pavel, S</creatorcontrib><creatorcontrib>Lesauvage, F</creatorcontrib><creatorcontrib>Gabriel, L</creatorcontrib><creatorcontrib>Danieau, F</creatorcontrib><creatorcontrib>Guarino, V</creatorcontrib><creatorcontrib>Schemoul-Berton, E</creatorcontrib><creatorcontrib>Oger, F</creatorcontrib><creatorcontrib>Fournel, C</creatorcontrib><creatorcontrib>Lauby, V</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taouk, B</au><au>Taouk, JB</au><au>Pavel, S</au><au>Lesauvage, F</au><au>Gabriel, L</au><au>Danieau, F</au><au>Guarino, V</au><au>Schemoul-Berton, E</au><au>Oger, F</au><au>Fournel, C</au><au>Lauby, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5PSQ-035 Relevance of fluoroquinolone prescription in hospital</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2018-03-01</date><risdate>2018</risdate><volume>25</volume><issue>Suppl 1</issue><spage>A180</spage><epage>A181</epage><pages>A180-A181</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundFluoroquinolones are frequently used in hospital for many indications. However, overuse or incorrect utilisation may cause resistance to these antibiotics. Furthermore, we had to analyse the consequences of a recently ofloxacine suppression from our hospital antibiotic list.PurposeWe wanted to know the level of relevance of fluoroquinolone prescription including: indication, fluoroquinolone molecule choice, dosage (including CKD-EPI based dose reduction), duration, route, eventual association, compliance with the antibiogram, drug interaction and catch of fluoroquinolone from 6 months before.Material and methodsWe carried out a 3 month transversal retrospective study. Between February and April 2017 each nominal prescription of fluoroquinolone was included using our pharmacy validation software. All services were included except intensives care units and emergencies. Then an intern in the pharmacy processed analyses of the relevance of the previous parameters with the help of senior infectious disease staff. The reference guideline used for relevance and analysis was the 2015 French Spoken Infectious Diseases Society (SPILF) recommendations.ResultsTwo hundred and six patients were included. The most recovered fluoroquinolone was levofloxacine 47.1% (95% CI: 40.3 to 53. 9). The average duration of treatment was 12 days (95% CI: 10.3 to 13.6). The most used route was oral 81.7% (95% CI: 76.2 to 87.2). In a large majority of fluoroquinolone prescription was probabilistic 60% (95% CI: 53.4 to 67.7).Analysis of relevance showed that indication was respected in 84.7% (95% CI: 79.5 to 89.8) of cases. The association of correct duration, dosage, molecule used and route was observed in 63.7% (95% CI: 53.8 to 73.6). 70.8% (95% CI: 58 to 83.7) of renal insufficiency patients (CKD-EPI &lt;60 ml/mn) received the exact dose reduction based on CKD-EPI. We identified the presence of a drug interaction in 13.8% (95% CI: 9 to 18,8) of prescriptions. Antibiotic association was noted in 42,7% (95% CI: 35,7 to 49,7) of prescriptions; only a few, 43.6%, (95% CI: 32.59 to 54.59) were relevant.ConclusionEven in the context of important changes in the fluoroquinolone list in our hospital, prescriptions are mostly relevant for indications and molecule choice. Serious medical information seems to be necessary concerning antibiotics associations. Adequate fluoroquinolone reduction dose must be a priority for renal insufficiency patients. Solutions available may be a special control using the biological software allied with pharmaceutical analysis targeted at low CKD-EPI patients.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2018-eahpconf.389</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A180-A181
issn 2047-9956
2047-9964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535190
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Antibiotics
Associations
Drug dosages
Drug interactions
Hospitals
Infectious diseases
Pharmacy
Prescriptions
Section 5: Patient safety and quality assurance
title 5PSQ-035 Relevance of fluoroquinolone prescription in hospital
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A41%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5PSQ-035%E2%80%85Relevance%20of%20fluoroquinolone%20prescription%20in%20hospital&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Taouk,%20B&rft.date=2018-03-01&rft.volume=25&rft.issue=Suppl%201&rft.spage=A180&rft.epage=A181&rft.pages=A180-A181&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2018-eahpconf.389&rft_dat=%3Cproquest_pubme%3E2010330170%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2010330170&rft_id=info:pmid/&rfr_iscdi=true